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Abstract
Previous studies have suggested that Lingzhi (Ganoderma lucidum) has antioxidant effects and possibly beneficial effects on blood
pressure, plasma lipids and glucose, but these have not been confirmed in subjects with mild hypertension or hyperlipidaemia. The objec-
tive of the present study was to assess the cardiovascular, metabolic, antioxidant and immunomodulatory responses to therapy with Lingzhi
in patients with borderline elevations of blood pressure and/or cholesterol in a controlled cross-over trial. A total of twenty-six patients
received 1·44 g Lingzhi daily or matching placebo for 12 weeks in a randomised, double-blind, cross-over study with placebo-controlled
run-in and cross-over periods. Body weight, blood pressure, metabolic parameters, urine catecholamines and cortisol, antioxidant
status and lymphocyte subsets were measured after each period. Lingzhi was well tolerated and data from twenty-three evaluable subjects
showed no changes in BMI or blood pressure when treated with Lingzhi or placebo. Plasma insulin and homeostasis model assessment-
insulin resistance were lower after treatment with Lingzhi than after placebo. TAG decreased and HDL-cholesterol increased with Lingzhi
but not with placebo in the first treatment period, but significant carry-over effects prevented complete analysis of these parameters. Urine
catecholamines and cortisol, plasma antioxidant status and blood lymphocyte subsets showed no significant differences across treatments.
Results indicate that Lingzhi might have mild antidiabetic effects and potentially improve the dyslipidaemia of diabetes, as shown
previously in some animal studies. Further studies are desirable in patients with hyperglycaemia.
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Lingzhi (Ganoderma lucidum) is a woody mushroom and
popular medicinal herb, which is widely used in China and
many other Asian countries(1). It has been attributed with a
range of beneficial effects including immunomodulation,
anti-cancer activity and enhancing longevity(2). The active
constituents include polysaccharides and oxygenated triter-
penoids, which have a broad range of biological activities
and pharmacological functions(3). In vitro studies with certain
extracts have shown effects which may benefit the cardiovas-
cular system including inhibition of cholesterol synthesis(4),
lowering of blood pressure by decreasing sympathetic outflow
from the central nervous system(5) and antioxidant effects(6–8).
Hypoglycaemic effects of an aqueous extract of the fruit
bodies of Lingzhi were identified many years ago and attribu-
ted to two glycans, ganoderans A and B(9). Subsequent studies
have shown that ganoderan B increased the plasma insulin
level in normal and glucose-loaded mice(9), and G. lucidum
polysaccharides lowered serum glucose and increased
insulin in normal fasted mice by facilitating Ca ion influx
into pancreatic b-cells(10). A recent study in lean (þdb/þm)
and obese/diabetic (þdb/þdb) mice has shown that a water
extract of Lingzhi lowered the serum glucose without a
change in insulin, with decreased hepatic expression of
phosphoenolpyruvate carboxykinase exerting greater effects
in diabetic mice than in lean mice(11). The diabetic mice also
showed decreases in LDL-cholesterol (LDL-C).
Short-term supplementation studies in healthy subjects have
shown an acute increase in plasma antioxidant capacity(12)
and after 4 weeks’ administration of a capsule formulation
(1·44 g Lingzhi/d; equivalent to 13·2 g fresh mushroom/d),
there was a trend towards lower plasma lipids and increased
urine antioxidant capacity(13). The antioxidant effects may
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also have benefits in diabetic patients. Elevated urine cortisol
and catecholamines, markers of stress and sympathetic hyper-
activity, are commonly found in hypertensive patients(14–17).
With the growing attention on herbal medicine usage,
there are insufficient well-designed clinical studies to support
the indications that may be suggested by the in vitro and
animal data.
The present study was undertaken to examine whether
Lingzhi had beneficial effects on a wide range of cardiovascu-
lar and metabolic parameters in patients with borderline
elevations of blood pressure and/or cholesterol comprehen-
sively, including lipids, glucose and insulin, in addition to
markers of antioxidant and oxidative stress status and lympho-
cyte subsets.
Subjects and methods
Subjects
A total of twenty-six patients with hypertension and/or dysli-
pidaemia were recruited from the outpatient clinic at the
Prince of Wales Hospital, the teaching hospital of The Chinese
University of Hong Kong, Shatin, Hong Kong. Pre-hyperten-
sive or stage 1 hypertension (classified by JNC7) subjects
with a systolic blood pressure of 130–150 mmHg or a diastolic
blood pressure of 85–100 mmHg, or with anti-hypertensive
treatment adjusted to the target blood pressure range,
were recruited for the present study. Patients with mild
to moderate elevation of plasma total cholesterol and/or
TAG (total cholesterol $ 6·0 mmol/l, or TAG $ 1·7 mmol/l and
TAG $ 5·0 mmol/l) with or without lipid-lowering treatment
were also enrolled. Patients with type 2 diabetes were
included if reasonably well controlled in terms of fasting glu-
cose and HbA1c (,8·5 %). Those with stable CHD could also
be included. Patients with recent cardiovascular events (within
6 months) or elevated plasma liver enzymes (.2 £ upper
limit of normal) were excluded. The present study was con-
ducted according to the guidelines laid down in the Declara-
tion of Helsinki and all procedures involving human
subjects/patients were approved by the Joint CUHK-NTEC
Clinical Research Ethics Committee. Written informed consent
was obtained at the time of enrolment from all subjects.
Study design and medication
This was a randomised, double-blind, cross-over study with
periods of treatment of 12 weeks each on Lingzhi treatment
or on matching placebo, two capsules twice daily. There
were periods of placebo run-in and cross-over, each of 4
weeks’ duration (Fig. 1). Subjects attended the study visits at
the end of the placebo run-in and placebo cross-over periods
and at the end of each period of 12 weeks’ treatment with pla-
cebo or Lingzhi. Capsules and matching placebo capsules
were prepared and supplied by Vita-Green Health Products
Company Limited (Hong Kong, China).
The Lingzhi extract was prepared as described previously(8).
The water-soluble polysaccharides from Lingzhi were isolated
and extracted with hot water (95–1008C). The concentrated
aqueous extract was further extracted with ethanol. The poly-
saccharide fraction (resulting precipitate) was collected by
centrifugation, followed by cleaning and drying. Crude extract
of Lingzhi was obtained by a second ethanol extraction and
vacuum concentration (608C, 76 mmHg). The Lingzhi extract
was standardised for batch-to-batch consistency with refer-
ence to authentic Lingzhi. Moreover, HPLC analysis on
two active ingredients, adenosine and ganoderic acid A, was
performed. A single stock of extract was prepared for the cap-
sules used in the present study. The dosage was 1·44 g Lingzhi
extract/d taken with two capsules (each capsule contains
360 mg extract) twice daily, which is equivalent to 13·2 g of
the fresh mushroom. This is within the recommended dose
of Lingzhi in the Chinese Materia Medica, with 11·25–18·75 g
of fresh material as the usual prescription. The safety of
each batch of Lingzhi extract was assured by testing for
heavy metals, pesticide residues and microbial levels.
Anthropometry, resting blood pressure measurement,
blood and urine sampling
Body weight was recorded, and blood pressure measured by
a semi-automatic sphygmomanometer (Critikon Dinamap; GE
Medical Systems Information Technologies, Louisville, KY,
USA). Fasting venous blood samples were taken at each base-
line and at the end of each 12-week treatment. With the collec-
tion period starting on the morning before the visit, 24 h urine
samples were obtained and the aliquots were stored at 2708C
until analysis.
Plasma haematology and biochemistry measurement
Standard haematology and biochemistry measurements
including electrolytes and lipid profile were performed in
the Department of Chemical Pathology, Prince of Wales Hos-
pital, Shatin, Hong Kong. Plasma glucose was measured using
a standard glucose oxidase method (Diagnostic Chemicals
Limited, Prince Edward, Canada) and apo-B by turbidimetric
assay, both with a Cobas Mira Analyzer (F Hoffman La
Roche Company Limited, Basle, Switzerland). Insulin was
measured by Active Insulin ELISA (Diagnostic Systems Labora-
tories, Inc., Webster, TX, USA).
Plasma antioxidant and oxidative stress status
measurements
Assessment of antioxidant status included measurement of
plasma total antioxidant power using the ferric-reducing/
antioxidant power assay (US patented)(18), ascorbic acid using
the ferric-reducing/antioxidant power-ascorbic acid assay(19),
a-tocopherol by HPLC (Waters Limited, Herts, UK) and calcu-
lation of lipid-standardised a-tocopherol(20). Allantoin was
measured by HPLC(19) and uric acid was measured by the
enzyme-linked spectrophotometric method (Biosystems, Bar-
celona, Spain). The antioxidant enzymes, superoxide dismutase
and glutathione peroxidase, were measured in erythrocytes
using the commercial kit methods (Randox Company, Antrim,
UK) and the enzyme activities standardised to Hb content.
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Lymphocyte subsets
The MultiTEST IMK Kit with TruCOUNT tubes (Becton
Dickinson, San Jose, CA, USA) and the lyse/no-wash method
were used for the assessment of absolute counts and the
ratio of CD4þ (T-helper lymphocytes), CD8þ (T-suppressor
lymphocytes and cytotoxic T-lymphocytes), natural killer
cells and B-lymphocytes in whole blood samples using a
four-colour FASCalibur flow cytometer (Becton Dickinson).
Urine electrolytes, catecholamines, cortisol and cortisone
measurements
Urine catecholamines including adrenaline, noradrenaline and
dopamine were measured by an HPLC method. Following
collection over a 24 h period, urine cortisol and cortisone were
measured by HPLC with tandem MS (liquid chromatography–
MS/MS) using an online sample clean-up method, modified
from the method of Taylor et al.(21). A triple-quadrupole API
2000 (Applied Biosystems, Foster City, CA, USA) was connected
to a Hewlett Packard Agilent 1100 Series LC system (Waldbronn,
Germany) for the analysis. The ratio of cortisol to cortisone in
urine reflects the activity of the 11-b hydroxysteroid dehydro-
genase type 2 (11-b HSD2) enzyme in the kidney(14).
Adverse effect assessment
At each visit, patients were asked to report any side effects or
change in their activity or well-being, and this information was
recorded. Compliance was assessed by counting the number
of capsules returned after every treatment period. There was
one subject with poor compliance who missed 2 weeks’
treatment. The data for this subject were not included in the
per-protocol analysis.
Statistical analysis
The data of twenty-three subjects were suitable for the analy-
sis, which was performed using SPSS (version 17; SPSS, Inc.,
Analysis
Follow-up
Not meeting inclusion
criteria (n 9)
Enrolment
Randomisation (n 26)
Assessed for eligibility (n 35)
Allocation
Loss to follow-up and
discontinued intervention (n 0)
Loss to follow-up and
discontinued intervention (n 0)
Cross-over
Analysed
(n 13, one subject excluded due
to epigastric discomfort)
Analysed
(n 10, one subject excluded due
to poor compliance)
Allocated to intervention
(n 11)
Received allocated intervention
(n 11)
Treatment
Allocated to placebo
(n 12)
Received allocated intervention
(n 12)
Discontinued intervention
(n 1, premature termination)
Placebo
Allocated to intervention
(n 14)
Received allocated intervention
(n 14)
Treatment
Allocated to placebo
(n 14)
Received allocated placebo
(n 14)
Placebo
Fig. 1. Consort diagram of patient recruitment in the Lingzhi study.
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Chicago, IL, USA). We first examined the normality of the data
by a Q–Q plot. Insulin, homeostasis model assessment-insulin
resistance, TAG and HDL-cholesterol (HDL-C) were log-trans-
formed due to skewness of the data. For a cross-over study, it
is important to test for any interaction between treatment and
time. Treatment £ time interactions between different par-
ameters and Lingzhi treatment effects were tested by a
mixed linear model to evaluate the treatment effects and
treatment £ time interaction in one single analysis. The
responses to placebo and Lingzhi from the two treatment
periods without significant interaction were combined for
the paired t test analysis. Because of significant treatment £
time interactions for HDL-C and TAG, only the results in the
first treatment period were analysed by an independent t
test, with thirteen subjects in the active treatment arm and
ten subjects in the placebo arm. The across-treatment changes
with placebo and with active treatment for the other variables
were evaluated by a paired-sample t test for two purposes:
first, testing any significant changes within the placebo or
Lingzhi group by comparing the pre- and post-treatment
data of each subject; second, testing the difference between
the placebo and treatment groups (subtracting the baseline
values by the end of treatment values) of various parameters.
Data are expressed as mean values and standard deviations,
unless otherwise indicated, with statistical significance set at
P,0·05.
Results
Baseline characteristics and medical history
From twenty-six eligible subjects enrolled in the study, one
withdrew due to personal reasons, one subject had poor com-
pliance (,80 % compliance from capsule counting) with
therapy and one subject had intercurrent illness; so their
data were not included in the per-protocol analysis (Fig. 1).
The demographic details, concomitant illnesses and medi-
cation use of the remaining twenty-three subjects according
to the randomisation to initial treatment with Lingzhi or pla-
cebo are shown in Table 1. There were seventeen subjects
receiving treatments for hypertension and five receiving
Table 1. Baseline anthropometric and clinical characteristics and plasma lipids of the patients in the per-protocol
analysis according to initial treatment
(Mean values, standard deviations, number of patients and percentages)
All subjects Placebo Lingzhi†
Mean SD Mean SD Mean SD
Male
n 23 10 13
% 43·5 50 38·5
Age (years) 54·8 8·1 53·2 6·7 56·0 9·3
SBP (mmHg) 135 10 138 9 134 10
DBP (mmHg) 81·0 6·8 82·2 7·8 80·1 6·1
Total body fat (%) 32·1 9·9 32·3 9·6 32·0 10·4
WHR 0·89 0·06 0·90 0·07 0·90 0·06
BMI (kg/m2) 26·4 4·3 26·8 3·9 26·1 4·90
TC (mmol/l) 5·97 0·80 5·85 0·70 6·05 0·80
LDL-C (mmol/l) 3·65 0·70 3·61 0·70 3·68 0·80
HDL-C (mmol/l) 1·37 0·30 1·26 0·20 1·46 0·40
TAG (mmol/l) 2·26 1·20 2·62 1·60 1·98 0·80
FPG (mmol/l) 5·47 0·80 5·31 0·50 5·58 0·90
Medical history (n)
Hypertension 17 5 12
Hyperlipidaemia 5 2 3
IFG/IGT/diabetes‡ 7 1 6
Medication record (n)
Anti-hypertensive medication§ 17 5 12
ACEI 2 1
a-Blocker 0 1
b-Blocker 1 3
CCB 5 9
Diuretic 1 5
Lipid-lowering medication (n)k 5 2 3
Statin 2 0
Fibrate 0 3
Aspirin 2 1 1
SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist:hip ratio; TC, total cholesterol; LDL-C, LDL-cholesterol; HDL-C,
HDL-cholesterol; FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; ACEI, angiotensin-
converting enzyme inhibitor; CCB, Ca channel blocker.
† No significant difference was found between baseline values of groups receiving placebo and Lingzhi.
‡ No subject in the study was taking any hypoglycaemic agent.
§ Patients having taken more than one anti-hypertensive medication were allowed to enter the study. Anti-hypertensive medications
include: ACEI – lisinopril; a-adrenergic blockers – prasosin; b-adrenergic blockers – atenolol and metoprolol; CCB – nifedipine,
lercanidipine, diltiazem and amlodipine; diuretics – indapamide, hydrochlorothiazide and triamterene.
k Lipid-lowering medications include: fibrate – gemfibrozil and bezafibrate; statin – atovastatin and simvastatin.
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treatments for hyperlipidaemia, which were not changed
during the study. Overall, seven patients had impaired fasting
glucose or impaired glucose tolerance and were treated with
diet alone.
Interaction analysis
Responses to the placebo and Lingzhi treatments are shown in
Table 2. TAG and HDL-C showed a statistically significant
carry-over effect (Fig. 2) whereas the other parameters did
not. Data for the two periods were pooled for further analysis
except for these two parameters and related ratios (LDL-
C:HDL-C and total cholesterol:HDL-C).
Anthropometric measurement and glycaemic indices
There were no significant changes in BMI, waist:hip ratio, and
systolic and diastolic blood pressure during treatment with
Lingzhi or placebo (Table 3). Plasma glucose and insulin
tended to increase during both treatment periods, but changes
tended to be smaller with Lingzhi treatment than with placebo.
The homeostasis model assessment-insulin resistance showed
a smaller increase after the Lingzhi treatment, but the differ-
ence was not statistically significant compared with placebo
(Table 3).
Lipid profile
Because of the treatment £ time interaction, changes in
plasma TAG and HDL-C were only analysed during the first
treatment (Table 2). TAG decreased by 8 % and HDL-C
increased by 24 % during the treatment with Lingzhi but not
with placebo. LDL-C increased to a similar degree with both
treatments, whereas apo-B increased significantly (P,0·02)
only during the placebo treatment (Table 3). A trend was
observed in absolute changes of apo-B values with placebo
and Lingzhi treatment.
Antioxidant and oxidative stress status
Changes in antioxidant capacity and oxidative stress showed
no significant differences between the treatments (Table 4).
There was a significant decrease in superoxide dismutase
during both placebo and Lingzhi treatments. There was a ten-
dency for the ratio of allantoin to uric acid to increase more
during the placebo period than during treatment with Lingzhi.
Lymphocyte subsets, urine catecholamines, cortisol and
cortisone
B-lymphocytes and T-helper cell counts and their percentages
decreased during the Lingzhi treatment, but the changes were
not different from those during the placebo treatment
(Table 5). The T-lymphocyte count decreased during the pla-
cebo treatment, but the change was not different from that
during the Lingzhi treatment. There were no significant differ-
ences between changes in plasma and urine electrolytes, 24 h T
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urine catecholamines, cortisol, cortisone or the cortisol:corti-
sone ratio during treatment with Lingzhi or placebo (Table 6).
Adverse effect evaluation
Both active Lingzhi and placebo were well tolerated. No
adverse effects in the laboratory safety parameters were
detected. A total of twenty-five adverse events were recorded,
nineteen during the placebo treatment and six during the
Lingzhi treatment (Table 7). None of these was considered
clinically significant and no subjects dropped out for reasons
which were thought to be related to study medication.
Discussion
Lingzhi, or G. lucidum, is well known in Chinese traditional
medicine and is reputed to promote good health and longev-
ity(1). However, scientific evidence from controlled trials in
human subjects is lacking and data from in vitro studies and
animal studies cannot always be extrapolated to the clinical
setting. Short-term studies in healthy subjects have indicated
that some antioxidant material is bioavailable from the same
Lingzhi formulation that was used in the present study(12). A
double-blind, placebo-controlled, cross-over study in healthy
subjects with the same dose (1·44 g Lingzhi/d) of the Lingzhi
capsule formulation used in the present study has shown a
tendency for reduction in LDL-C after 4 weeks’ treatment
with Lingzhi compared with a tendency to increase after
placebo(13). We considered that repeating the study in patients
with higher baseline levels of LDL-C and having a longer
period of treatment might produce a more definitive effect.
However, we did not find any benefit on the LDL-C as the
levels increased during both the placebo and Lingzhi treat-
ment periods.
The effects on HDL-C and TAG were complicated by a
treatment £ time interaction, and it was felt appropriate to
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Fig. 2. Changes in (a) HDL-cholesterol (HDL-C) and (b) TAG during the study treatments. Values are means, with their standard errors represented by vertical
bars for subjects randomised to the first group (Lingzhi as the first treatment followed by placebo (–A–, n 13)) and the second group (taking placebo in the first
period, then switched to the Lingzhi treatment (–K–, n 10)). There was no significant difference between the baseline and after 12 weeks’ treatment of the two
groups, while the data showed a significant carry-over effect in these two parameters, HDL-C and TAG.
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Table 3. Changes in blood pressure, anthropometric measurements, glycaemic control parameters and plasma lipid profile for the twenty-three patients with 12 weeks’ treatment with placebo
or Lingzhi
(Mean values, standard deviations or 95 % confidence intervals)
Placebo (n 23) Lingzhi (n 23)
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline‡
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline‡§
P (treatment £ time
interaction)Mean SD Mean SD Mean 95 % CI Mean SD Mean SD Mean 95 % CI
Blood pressure
SBP (mmHg) 140 9 138 14 22 27, 3 135 11 136 12 1 24, 6 0·068
DBP (mmHg) 84·3 8·9 81·5 9·7 22·8 25·4, 0·4 80·6 7·7 82·6 8·9 2·0 20·6, 4·7† 0·184
Anthropometric measurements
WHR 0·91 0·10 0·91 0·10 0·01 0, 0·02 0·90 0·10 0·91 0·10 0·02 0, 0·03 0·759
BMI (kg/m2) 26·6 4·3 26·8 4·4 0·2 0·0, 0·4 26·6 4·3 26·6 4·3 0·0 20·3, 0·3 0·744
Glycaemic control
FPG (mmol/l) 5·47 0·70 5·63 0·70 0·16 0, 0·32 5·46 0·80 5·57 0·70 0·11 20·12, 0·34 0·552
Insulin (mIU/ml)k{ 12·5 14·6 1·2 1·0, 1·4 14·0 13·3 1·0 0·8, 1·1 0·336
95 % CI 9·9, 15·7 11·5, 18·5 11·3, 17·4 10·8, 16·3
HOMA-IR 2·99 3·60 1·20 1·01, 1·42 3·34 3·24 0·97 0·80, 1·17 0·373
95 % CI 2·31, 3·87 2·76, 4·70 2·59, 4·32 2·55, 4·12
Lipid profile
TC (mmol/l) 6·04 0·80 6·45* 1·00 0·41 0·05, 0·77 6·19 0·80 6·49 0·90 0·30 20·20, 0·63 0·920
LDL-C (mmol/l) 3·70 0·70 4·09*** 0·09 0·40 0·08, 0·71 3·61 0·90 3·97** 0·90 0·36 0·07, 0·65 0·908
Apo-B (mg/l) 1210 180 1310** 240 100 20, 190 1250 210 1290 220 40 230, 100 0·574
LDL-C:apo-B 256 268 12 23, 27 263 265 2 227, 32 0·237
95 % CI 225, 286 235, 301 230, 295 228, 301
SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist:hip ratio; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment-insulin resistance; TC, total cholesterol; LDL-C, LDL-cholesterol.
Mean values were significantly different from those of respective baseline: *P,0·05, **P,0·02, ***P,0·005.
† Mean values were significantly different from those of the placebo group (P,0·05).
‡ Absolute change ¼ value of end of treatment 2 value of baseline.
§ No significant difference was found between the responses to the placebo and Lingzhi groups by paired t test comparison, unless specified.
k Insulin, HOMA-IR and HDL-cholesterol were analysed with natural log transformation due to skewness of the data.
{ 1mIU/ml ¼ 6·945 pmol/l.
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Table 4. Changes in antioxidant and oxidative stress status parameters for the twenty-three patients with 12 weeks’ treatment with placebo or Lingzhi
(Mean values, standard deviations or 95 % confidence intervals)
Placebo (n 23) Lingzhi (n 23)
P (treatment £
time interaction)
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†‡
Mean SD Mean SD Mean 95 % CI Mean SD Mean SD Mean 95 % CI
Antioxidant levels
FRAP (mmol/l) 1320 239 1252 266 268 2180, 45 1336 224 1348 183 12 289, 114 0·169
Ascorbic acid (mmol/l) 54·6 23·3 54·6 15·5 0·0 213·5, 13·5 61·8 19·2 57·7 13·9 24·2 213·5, 5·2 0·231
Oxidative stress status
a-Tocopherol (mmol/l) 37·8 11·4 37·3 10·1 20·4 22·6, 1·8 38·0 10·7 38·7 12·3 0·7 22·8, 4·3 0·282
Vit E LS (mmol/mmol TC þ TAG) 5·10 1·00 5·10 1·30 20·01 20·05, 0·03 5·30 1·20 5·10 1·20 0·02 20·07, 0·02 0·165
Allantoin (mmol/l) 80·6 32·0 84·6 29·3 4·0 14·0, 22·0 72·5 20·3 79·0 14·7 6·5 23·5, 16·4 0·403
Allantoin:uric acid ratio 0·25 0·08 0·30 0·12 0·03 20·03, 0·09 0·24 0·10 0·27 0·13 0·02 20·01, 0·05 0·280
Malondialdehyde (mmol/l) 1·73 0·20 1·78 0·20 0·05 20·04, 0·14 1·76 0·20 1·79 0·20 0·04 20·05, 0·12 0·836
Erythrocyte GPx (U/g Hb) 52·3 15·4 51·0 15·5 22·7 26·9, 1·6 54·5 20·2 53·0 20·4 21·4 24·8, 1·9 0·080
Erythrocyte SOD (U/g Hb) 1486 183 1188*** 244 2297 2403, 2192 1466 217 1234*** 316 2229 2350, 107 0·854
FRAP, ferric-reducing/antioxidant power (plasma total antioxidant power); Vit E LS, vitamin E lipid standardised; TC, total cholesterol; GPx, glutathione peroxidase; SOD, superoxide dismutase.
*** Mean values were significantly different from those of respective baseline (P,0·005).
† Absolute change ¼ value of end of treatment 2 value of baseline.
‡ No significant difference was found between the responses to the placebo and Lingzhi groups, by paired t test comparison.
Table 5. Changes in lymphocyte subsets for the twenty-three patients with 12 weeks’ treatment with placebo or Lingzhi
(Mean values, standard deviations or 95 % confidence intervals)
Placebo (n 23) Lingzhi (n 23)
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†‡
P (treatment £ time
interaction)Mean SD Mean SD Mean 95 % CI Mean SD Mean SD Mean 95 % CI
Neutrophil count (mm3) 61·4 7·6 63·6 7·8 220·9 251·8, 9·9 60·9 5·8 61·4 6·3 14·6 26·7, 35·9 0·531
Lymphocytes (%) 28·9 6·8 27·4 6·4 21·5 23·9, 0·8 30·6 6·9 28·8 5·7 21·8 24·7, 1·2 0·643
B-lym (CD19, mm3) 267 94 262 104 4·5 227·8, 17·7 295 100 258*** 70·8 236·8 259·8, 213·8 0·095
B-lym (%) 15·6 3·2 16·2 3·3 20·3 29·6, 9·1 16·6 3·6 15·8** 3·4 29·6 216·1, 23·0 0·127
T-lym (CD3, mm3) 1172 327 1108* 305 264 2127, 1 1184 269 1110 243 274 2182, 34 0·058
T-helper cells (CD4, mm3) 768 279 735 228 251 2100, 21 776 212 718* 196 257 2132, 17 0·156
T-helper cells (%) 45·2 6·2 44·6 6·7 24·1 210·1, 1·8 44·9 6·0 43·4* 6·7 25·1 213·1, 2·9 0·780
T-supp cells (CD8, mm3) 365·6 110·7 356·9 131·0 28·7 243·2, 25·8 368·9 111·9 363·2 116·5 25·7 244·2, 32·9 0·227
CD4:CD8 ratio 1·21 0·40 1·20 0·30 20·01 20·11, 0·10 1·21 0·30 1·24 0·40 20·08 20·22, 0·06 0·623
B-lym, B-lymphocytes; T-lym, T-lymphocytes; T-supp cells, T-suppressor cells.
Mean values were significantly different from those of respective baseline: *P,0·05, **P,0·02, ***P,0·005.
† Absolute change ¼ value of end of treatment 2 value of baseline.
‡ No significant difference was found between the responses to the placebo and Lingzhi groups, by paired t test comparison.
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Table 6. Changes in plasma electrolytes and urinary electrolytes, cortisol, cortisone and catecholamines for the twenty-three patients with 12 weeks’ treatment with placebo or Lingzhi
(Mean values, standard deviations or 95 % confidence intervals)
Placebo (n 23) Lingzhi (n 23)
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†
Baseline
(0 weeks)
End of treatment
(12 weeks)
Absolute change
from baseline†‡
P (treatment £ time
interaction)Mean SD Mean SD Mean 95 % CI Mean SD Mean SD Mean 95 % CI
Plasma and urine electrolytes
Pl K (mmol/l) 3·63 0·40 3·85** 0·50 0·21 0·04, 0·39 3·77 0·40 3·76 0·50 20·02 20·18, 0·14 0·099
Pl Na (mmol/l) 140·4 2·0 140·5 1·8 0·2 20·7, 1·1 140·7 1·7 140·7 2·4 0·0 21·0, 1·1 0·988
U K (mmol/d) 48·6 21·9 50·8 17·1 2·2 24·3, 8·8 48·2 12·2 48·2 22·6 0·1 28·6, 8·7 0·821
U Na (mmol/d) 185 94 185 81 0·2 232·5, 32·9 165 84 167 78 1·9 238·7, 42·5 0·846
Mineralocorticoids and metabolite ratio
Cortisol:cortisone ratio§ 0·31 0·10 0·33 0·20 0·03 20·06, 0·11 0·30 0·10 0·32 0·10 0·03 20·03, 0·08 0·286
Cortisol (nmol/d) 55·7 38·4 61·2 49·8 5·5 211·0, 22·0 48·0 33·4 61·8 38·3 13·7 21·4, 28·8 0·105
Cortisone (nmol/d) 186 101 188 87 3 237, 43 159 91 187 78 28 21, 57 0·395
Catecholamines
Noradrenaline (nmol/d) 189 96 195 84 6 224, 36 151 65 204*** 58 52 21, 84 0·123
Adrenaline (nmol/d) 39·6 21·3 29·9 13·4 29·7 222·7, 3·3 39·1 20·1 35·9 17·8 23·2 233·4, 27·0 0·229
Dopamine (nmol/d) 1036 506 1000 412 236 2189, 118 950 532 998 431 48 2141, 236 0·549
Pl K, plasma potassium; Pl Na, plasma sodium; U K, urine potassium; U Na, urine sodium.
Mean values were significantly different from those of respective baseline: **P,0·02, ***P,0·005.
† Absolute change ¼ value of end of treatment 2 value of baseline.
‡ No significant difference was found between the responses to the placebo and Lingzhi groups, by paired t test comparison.
§ Activity of 11-b hydroxysteroid dehydrogenase type 2: the ratio of urinary cortisol to cortisone (value of 24 h cortisol output/value of 24 h cortisone output).
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only compare the responses during the first period of treat-
ment so that the numbers in the groups compared in parallel
are too small to show significant differences. The treatment £
time interaction of TAG and HDL-C might be due to the
changes in the diet or lifestyle of the subjects, or other factors
related to taking part in a clinical study. The increase in HDL-C
and the decrease in TAG seen with the Lingzhi treatment
would be compatible with the improvement in dyslipidaemia
associated with diabetes when glycaemic control or insulin
sensitivity improves(22). In the study of Lingzhi extract in
obese/diabetic (þdb/þdb) mice, the decrease in plasma glu-
cose with the higher dose was accompanied by a decrease
in LDL-C without an increase in HDL-C(11). It has been
suggested that db/db mice are a useful model for diabetic dys-
lipidaemia, but the main lipid abnormality in these mice is an
increase in LDL-C in small dense particles rather than elevated
TAG and decreased HDL-C as found in human subjects(23). As
mice do not have cholesteryl ester transfer protein, the inverse
relationship between HDL-C and TAG will differ from that in
human subjects(24). The expression of human cholesteryl
ester transfer protein in db/db mice reduced VLDL-C and
LDL-C and prevented the formation of diet-induced aortic
atherosclerotic plaques(25).
We have previously shown that patients with rheumatoid
arthritis have insulin resistance and dyslipidaemia and that
treatment with the TNF-a inhibitor infliximab improved insu-
lin resistance, reduced C-reactive protein and increased
HDL-C(26). There was also an increase in LDL-C, but the
LDL:apo-B ratio remained unchanged, which may suggest
that LDL particle size increased, which would be compatible
with an improvement in insulin resistance(27). The same may
be true in the present study where LDL-C appeared to increase
more than apo-B with Lingzhi, suggesting that LDL particle
size may have increased.
Insulin resistance and inflammation are associated and
some anti-inflammatory treatments may improve insulin resist-
ance as in the study with infliximab(26). Lingzhi extracts have
been shown to suppress inflammation and have free radical-
scavenging and anti-cancer effects in various in vitro
studies(6,8,28). In a placebo-controlled study in patients with
rheumatoid arthritis, a combination of Lingzhi (4 g) and San
Miao San (2·4 g), which contains Rhizoma atractylodis
(Cangzhu), Cortex phellodendri (Huangbai) and Radix achyr-
anthes Bidentatae (Niuxi), showed a mild analgesic effect but
no obvious anti-inflammatory action(29). The ex vivo-induced
level of inflammatory cytokine IL-18 was lower in the group
receiving active treatment, which suggested a beneficial
immunomodulatory effect(30). Findings in a rat model of
arthritic knees also suggested that the Lingzhi and San Miao
San formulation had analgesic and anti-inflammatory
effects(31). Another study(32) in healthy subjects has shown a
tendency for an increase in the count of cells expressing
CD56, which identifies natural killer lymphocytes, after 10 d
treatment with Lingzhi. We did not find any significant effect
on the changes in lymphocyte subsets with Lingzhi compared
with placebo in the present study.
Urine cortisol and catecholamines were measured as
markers of stress and sympathetic activity. There were no
significant differences in changes with Lingzhi compared
with those with placebo. The ratio of cortisol to cortisone in
urine can be used as a marker of the activity of 11-b HSD2
in the kidney and changes in this have been associated with
hypertension and insulin resistance(14). The 11-b HSD2
enzyme is also inhibited by glycyrrhizic and glycyrrhetinic
acids in licorice from Glycyrrhiza glabra, the roots of which
are very commonly used in Chinese traditional medicine as
gancao(33). Hypertensive patients were found to be more sen-
sitive to the inhibition of 11-b HSD2 enzyme by gancao(34).
Urine cortisol and cortisone tended to increase with Lingzhi
treatment, but this was not significantly different from placebo
and there was no change in the cortisol:cortisone ratio.
The present study should be considered exploratory in
nature, as the number of patients was small and many differ-
ent markers were measured, some of which show quite a high
biological variation. It was undertaken primarily to look at
effects on blood pressure and cholesterol by selecting patients
with higher baseline levels of these parameters. The findings
of changes in HDL-C, TAG and, potentially, in insulin resist-
ance are of interest and are compatible with some of the
animal and in vitro studies. This kind of carefully designed
and controlled study is needed to provide evidence to support
the clinical use of herbal medicines. Further studies with
Lingzhi treatment in patients with more obvious hyperglycae-
mia with diabetes, or the metabolic syndrome, would be
useful to determine whether these abnormalities can be
ameliorated.
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Table 7. Subjective symptoms and adverse events reported by the
twenty-three mild dyslipidaemic and hypertensive patients
Adverse events
No. of
events
Lingzhi
period
Placebo
period
Headache or heaviness of head 6 3 3
Easy tiredness 2 0 2
Chest discomfort 4 0 4
Epigastric discomfort 2 0 2
Influenza/running nose 3 1 2
Sore throat 4 1 3
Others 4 1 3
Total 25 6 19
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